Porphobilinogen synthase inhibitors are a class of chemical compounds that disrupt the enzymatic function of porphobilinogen synthase (PBGS), an enzyme crucial to the biosynthesis of tetrapyrroles, such as heme and chlorophyll. PBGS, also known as δ-aminolevulinic acid dehydratase (ALAD), catalyzes the condensation of two molecules of δ-aminolevulinic acid (ALA) to form porphobilinogen, the first pyrrole intermediate in the tetrapyrrole biosynthetic pathway. Inhibition of PBGS can result in the accumulation of ALA, which disrupts the normal progression of tetrapyrrole synthesis. This accumulation can lead to oxidative stress in biological systems, as ALA is prone to forming reactive oxygen species (ROS) when it builds up. Inhibitors of PBGS typically work by interfering with the enzyme's active site, binding to essential metal cofactors such as zinc or magnesium, or altering the enzyme's quaternary structure, ultimately preventing its catalytic function.
The inhibition of PBGS can occur through a variety of mechanisms, depending on the chemical nature of the inhibitor. Some inhibitors are heavy metal ions like lead, which strongly bind to the enzyme's active site and displace necessary cofactors. Other inhibitors may act as substrate analogs, mimicking ALA but failing to undergo condensation, effectively stalling the enzymatic process. Moreover, certain organic molecules can inhibit PBGS through allosteric mechanisms, wherein binding at a non-active site changes the enzyme's conformation and diminishes its activity. The structural complexity of PBGS, which often exists as a multimeric enzyme, adds an additional layer of regulation, making it sensitive to inhibitors that influence its oligomerization state. Understanding the chemical interactions between PBGS and its inhibitors is vital for comprehending how disruptions in this pathway can lead to broader biochemical consequences, particularly in organisms that rely heavily on efficient tetrapyrrole synthesis for metabolic processes such as respiration and photosynthesis.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, can directly lead to the hyperacetylation of histones near the PBGS gene, potentially resulting in the downregulation of its expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
By inhibiting DNA methyltransferase, 5-Azacytidine can cause hypomethylation of the PBGS gene promoter, potentially decreasing its expression levels. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D binds tightly to DNA at the transcription initiation complex, preventing RNA polymerase from advancing and thereby reducing transcription of the PBGS gene. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
α-Amanitin selectively inhibits RNA polymerase II, which can lead to a decrease in mRNA synthesis for the PBGS gene, resulting in lower protein levels. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide blocks the translocation step in protein synthesis on ribosomes, which would lead to a decrease in the synthesis of the PBGS enzyme. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which can result in the decreased translation of mRNA into proteins, including the potential inhibition of PBGS synthesis. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid can alter gene expression by activating retinoic acid receptors that may bind to the PBGS promoter region and decrease its gene transcription. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
Mycophenolic acid inhibits inosine monophosphate dehydrogenase, leading to depletion of guanosine nucleotides and potentially reducing PBGS mRNA expression. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium butyrate induces hyperacetylation of histones, which could lead to a condensed chromatin structure around the PBGS gene, resulting in reduced transcription. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $107.00 | 3 | |
Spironolactone, through its anti-mineralocorticoid effects, could lead to the downregulation of PBGS by altering transcription factor binding to the PBGS gene promoter. | ||||||